ablynx
Ablynx Grants Eddingpharm License To Develop Anti-RANKL Nanobody
Ablynx has granted a license to Eddingpharm to develop and commercialize its anti-RANKL Nanobody, ALX-0141, in China, Hong Kong, Macau and Taiwan.
Ablynx has granted a license to Eddingpharm to develop and commercialize its anti-RANKL Nanobody, ALX-0141, in China, Hong Kong, Macau and Taiwan.
